 |
 Video: What is a Stock Split?
|
|
|
| Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors. According to our Allogene Therapeutics stock split history records, Allogene Therapeutics has had 0 splits. | |
|
Allogene Therapeutics (ALLO) has 0 splits in our Allogene Therapeutics stock split history database.
Looking at the Allogene Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Allogene Therapeutics shares, starting with a $10,000 purchase of ALLO, presented on a split-history-adjusted basis factoring in the complete Allogene Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/12/2018 |
|
| End date: |
04/18/2024 |
|
| Start price/share: |
$26.81 |
|
| End price/share: |
$3.46 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-87.09% |
|
| Average Annual Total Return: |
-30.99% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,290.35 |
|
| Years: |
5.52 |
|
|
|
|
|
